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High smoking rates in people with serious mental illness (SMI) contribute significantly to 
their disproportionately high morbidity and premature mortality. There is an urgent need to 
help people with SMI quit smoking. This paper: critically discusses competing explanations 
for the high rates of smoking in persons with SMI and the effectiveness of available smoking 
cessation interventions. It argues for trialing harm reduction options, such as NRT and e-
cigarettes as long term substitutes for cigarettes in smokers with SMI who are unable to quit. 
Smoke free psychiatry units should provide smoking cessation support on admission and after 
discharge. 
 Introduction  
Serious mental illnesses (SMI) include diagnosable mental, behavioural or emotional 
disorders which cause serious functional impairment, and substantially interfere with or limit 
one or more major life activities.1The prevalence of cigarette smoking in persons with SMI 
such as schizophrenia, schizoaffective disorders, bipolar disorder and, major depression, is 
much higher than in the general population.2,3 The association of smoking is strongest and 
most consistent in persons with schizophrenia who are 3-7 times more likely to smoke 
compared to general population,4,5 Those with bipolar disorder 3-4 times more likely6 and 
those with major depression are twice as likely to smoke,7 as people without these disorders. 
Tobacco smoking is a major contributor to the high premature mortality and severe morbidity 
in persons with SMI.2 Heavy daily smoking in combination with limited access to quality 
health care and dyslipidaemia produced by some antipsychotic medication increases the risk 
of cancers and heart disease 8,9 and reduces life expectancy by 10-15 years compared to 
people without SMI.10 SMI is also associated with dependence on alcohol and other 
substances which further compounds their risk of adverse health outcomes.11–14  
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What should be done to reduce smoking in persons with serious mental illnesses?15 The 
answer depends on answers to the following questions: What factors drive the high 
prevalence of smoking in this population? How easy or difficult it is for persons with SMI to 
quit smoking? Are smoke free psychiatric facilities an appropriate policy response? Should 
we consider tobacco harm reduction (THR), i.e. encouraging heavy smokers with SMI to use 
non-smoked nicotine products instead of smoking tobacco?  
Smoking in SMI: Cause or effect? 
A number of theories attempt to explain the high smoking prevalence in people with SMI, 
especially schizophrenia and major depression. These hypotheses are based on one of the 
following premises - SMI causes smoking (self-medication hypothesis) 16,17, smoking causes 
SMI (causal hypothesis) and both smoking and SMI result from a common aetiology (shared 
vulnerability hypothesis).18,19 A summary of evidence for and against each of these 
hypotheses are presented in Table 1. 
These three hypotheses have different implications for policies to reduce cigarette smoking in 
persons with SMI. The self-medication and the shared vulnerability hypotheses may be seen 
as favouring more lenient policies towards cigarette smoking in these persons. This could 
include THR using alternative non-combustible nicotine products such as pharmaceutical 
nicotine products, smokeless tobacco and nicotine vaporisers, such as, e-cigarettes. The 
causal hypothesis on the other hand may be seen as justifying an intensification of efforts to 
discourage smoking in persons with SMI (e.g. hospital smoking bans) with the aim of 
encouraging abstinence from all forms of nicotine. Evidence for causality should be weighed 
individually for different mental illnesses when deciding upon these tobacco control policies. 
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Smoking cessation in people with mental illness 
Smoking uptake is higher and cessation rates are lower in people with SMI than without 
SMI.6,20 Persons with SMI are also often heavily dependent on nicotine21 and experience 
more severe withdrawal symptoms when they stop smoking than people without SMI.22 Co-
existing alcohol and substance abuse may potentiate the reinforcing effects of nicotine, 
making quitting even more difficult for those with multiple dependence diagnoses.13,23 
Despite these barriers, people with SMI report that they are as motivated to stop smoking as 
people without SMI.24 The low cessation rate among people with SMI has been attributed to a 
combination of a failure to promote smoking cessation in this population and the difficulty 
that they have in accessing smoking cessation services.9,25,26 
Smokers with SMI, like all smokers, can improve their physical and mental health by 
quitting.27 However, many of these smokers, and the mental health professionals who care for 
them, believe that their mental health will worsen if they quit smoking. For this reason staff 
may not encourage quit attempts.25This belief is inconsistent with the evidence that smoking 
cessation reduces depression, anxiety and stress, people with SMI.27 
Smoking cessation guidelines for all smokers including those with SMI recommend 
pharmacotherapy in combination with behavioural interventions.28,29 The most effective 
pharmacotherapies include nicotine replacement therapy (NRT), the atypical anti-depressant 
bupropion and varenicline, a nicotinic receptor partial agonist.30 Behavioural interventions 
include brief advice, financial incentives for quitting, self-help material and 
counselling.28,29,31 
The effectiveness of these smoking cessation pharmacotherapies has been demonstrated in 
numerous clinical trials in the general population32–34 but it has not been extensively tested in 
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people with SMI.35 Concerns about the side effects of varenicline and bupropion have 
promoted caution in the use of these drugs in this people with SMI. A network meta-analysis 
of 14 RCTs of smoking cessation pharmacotherapies in smokers with SMI found that 
bupropion and varenicline were both effective and acceptable (OR= 4·51 and 5·17 
respectively).30 However, the evidence base was rated as of very low in quality.30 Some 
studies suggest that NRT may be effective in reducing smoking and maintaining abstinence 
in the long term in smokers with SMI.36,37 
Behavioural support for smoking cessation in people with SMI is effective at long term 
follow up (RR 1·33, CI 0·96–1·8),38 so too is ppharmacotherapy combined with counselling 
or motivational interviewing, or alone.39–41 Mobile phone based support and internet assisted 
cessation is effective in general population, but have not been well studied in smokers with 
SMI.42–44 It is unclear which smoking cessation options are best for people with SMI but the 
limited evidence suggests that those that work for smokers in the general population may also 
be effective for smokers with SMI with or without co-morbid substance abuse disorders.40,45 
Abstinence from tobacco may also reduce relapse to substance abuse in people with co-
morbid mental illness.45 
Smoking bans in psychiatric units 
Public bans have reduced population smoking prevalence by de-normalising smoking and 
making it  inconvenient to smoke.46 Similar bans have been adopted in healthcare settings for 
more than 20 years in the USA and 10 years in Australia47,48 but these bans have been slowly 
and inconsistently implemented in mental health facilities.49,50 The high prevalence of heavy 
smoking among the patients and staff sympathy for patients who have been denied the 
opportunity to smoke have probably played a role.51 (Table 2) 
Author post print- please refer to published version:  
Sharma R, Gartner CE, Hall WD. The challenge of reducing smoking in people with serious mental illness. Lancet 
Respir Med 2016; 4: 835-44 at http://dx.doi.org/10.1016/S2213-2600(16)30228-4 
 
6 
 
 Smoking bans in psychiatric inpatient units in Australia52 have attracted a number of 
criticisms. One is that bans in secure psychiatric units are “cruel and inhumane” because they 
deny the “right to smoke” to patients who are involuntarily detained.53,54 These critics suggest 
that these patients should be allowed to smoke in designated smoking areas so as to protect 
non-smokers while allowing smokers with SMI the right to harm only themselves.55,56 Those 
who defend smoking bans in mental health facilities argue that designated smoking areas 
convey the message that smoking is acceptable for persons with SMI.57  
Critics of smoking bans have also blamed them for acts of violence against staff, often on the 
basis of very weak evidence.58–60 These critics place greater weight on rare acts of violence to 
staff and patients than on the far larger harms that smoking causes to patients.  
Smoking bans have also been criticised as paternalistic violations of individual freedom that 
deprive patients with SMI of “one of their few remaining pleasures”.54,55 This claim assumes 
that smokers with SMI do not want to or cannot quit smoking when almost as many want to 
quit as smokers without mental illnesses.24 They simply find it more difficult to do so because 
they are not encouraged or adequately supported in quit attempts and they spend considerable 
periods of time being in a social environment which normalises and reinforces heavy 
smoking.57 For people with SMI in long-term residential care, smoking bans may represent 
enforced smoking cessation because smoking is not permitted on the premises and patients 
cannot leave the facility to smoke. This situation raises more ethical concerns but smoking is 
one of many freedoms that people living in these circumstances lose. 
Cigarette smoking is highly addictive and quitting can be extremely challenging for very 
heavy smokers with SMI. Smoking bans may give these patients a chance to quit in the most 
favourable setting, without an opportunity to smoke, and with good access to medications and 
psychological support from health care professionals to manage their withdrawal 
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symptoms.51 These advantages may be partially offset if bans deter smoking patients from 
seeking treatment although it remains to be seen how commonly this occurs.58  
Another concern is increased toxicity from anti-psychotic medications (for e.g. clozapine and 
olanzapine) if persons on these medications abruptly stop smoking. In such cases, treating 
psychiatrists should make appropriate adjustments in drug dosage, monitor the person while 
an in-patient and arrange for dosage review after discharge, if the person resumes 
smoking.61,62 
Smoking bans alone will not produce long term abstinence.63  A humane policy would 
provide patients with access to nicotine while in hospital e.g. by providing NRT, counselling 
and other pharmacotherapy on admission. Cessation support should also be provided at 
discharge, and on return to the community.64 This approach has encouraged post discharge 
quit attempts in patients discharged from a smoke free psychiatric hospital.65 Government 
policies which subsidise pharmacotherapies and harm reduction options for people with SMI 
may be needed to help maintain abstinence. Training hospital staff in quit smoking and 
relapse prevention methods and correcting their misapprehensions about the effects of 
smoking bans could increase compliance with smoke free policies and reduce patient 
distress.49,66 
Tobacco harm reduction  
The most effective way to eliminate tobacco-related harm is to abstain from using any 
tobacco or nicotine products. This has long been the central aim of tobacco control policy. 
But should smokers who are unable to quit, or who take longer to quit, be encouraged to try 
THR, that is, to obtain nicotine in ways that are much less harmful than smoking cigarettes 
e.g. by using smokeless tobacco or e-cigarettes?    
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Contemporary public health discourse about THR is highly polarized, especially in the case 
of e-cigarettes. Opponents argue that e-cigarettes will deter smokers from quitting, serve as a 
gateway to tobacco smoking in adolescents and renormalize smoking. These concerns may 
only be properly assessed after years of observational research on the ways in which these 
products are used by smokers and non-smokers and their impact on smoking rates.   
Opponents of THR believe that these potential risks are sufficiently severe to warrant pre-
emptive bans on the sale of e-cigarettes.  They would only allow their use for cessation if 
they are shown to be safe and effective for cessation. This approach is likely to limit 
smokers’ access to e-cigarettes produced by the tobacco and pharmaceutical industries, the 
commercial entities best able to meet the large regulatory costs. This is the current policy in 
Australia and Canada and a policy advocated elsewhere. 
In countries that have banned e-cigarettes, it is important to examine how well e-cigarettes 
help heavily addicted smokers (such as those with SMI) to either quit all nicotine use, or to 
switch to using these as a safer long term alternative to cigarette smoking. There are very 
good reasons why heavy smokers with SMI should be a high priority group for assessing the 
value of THR approaches.67 These are summarised below. 
1. Some people with SMI may be deterred from quitting smoking because they believe 
that smoking alleviates their depression and attentional-cognitive deficits and reduces 
the adverse effects of antipsychotic drugs.17,68,69 They may receive little support and 
encouragement from mental health personnel to quit because of unfounded fears 
about destabilising their mental condition.25 
2. Switching to non-smoked nicotine products could reduce the dose of some 
antipsychotic medicines required, because the non-nicotine components of tobacco 
Author post print- please refer to published version:  
Sharma R, Gartner CE, Hall WD. The challenge of reducing smoking in people with serious mental illness. Lancet 
Respir Med 2016; 4: 835-44 at http://dx.doi.org/10.1016/S2213-2600(16)30228-4 
 
9 
 
smoke increase the metabolism of some antipsychotic drugs which means that 
smokers need higher drug doses to achieve optimum plasma levels.70 
3. People with SMI are more often exposed to social environments that promote heavy 
smoking e.g. spending time with peers and family members who smoke tobacco. This 
makes abstinence difficult to maintain.71  
4.  Smokers with SMI, especially those with psychotic illnesses are often socio-
economically disadvantaged and spend a large proportion of their meagre income on 
cigarettes. Access to low cost or subsidised harm reduction products would not only 
be beneficial for their health by quitting cigarettes but would make more of their 
limited income available for living expenses. 
5. People with SMI may struggle to quit smoking successfully because of their heavy 
dependence on nicotine.20 Previous failed quit attempts could reduce confidence in 
making future quit attempts.72,73 This may be expose them to smoking for much 
longer than other smokers. THR options used as an interim step towards quitting may 
reduce tobacco-related harms sooner and encourage quitting.   
6. THR for smokers with SMI, would satisfy important bioethical principles of 
beneficence (doing good), non-maleficence (protecting from harm), autonomy 
(respecting individual freedoms) and justice.74 It may also reduce some of the ethical 
concerns about enforced cessation in smoke-free mental health facilities, if residents 
are permitted to use non-smoked nicotine products. 
Potential tobacco harm reduction products 
Among the THR products that could be recommended are NRT, low nitrosamine smokeless 
tobacco products (for example snus) and e-cigarettes. NRT substantially reduces smoking in 
smokers with SMI.75 There is insufficient evidence to justify the routine use of other harm 
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reduction products but there is enough evidence to justify clinical trials. For example, one 
clinical trial found that e- cigarettes and nicotine patches were equally effective in achieving 
abstinence at 6 months and equally acceptable to smokers taking medications for mental 
illness. 76 Another found that e- cigarettes significantly reduced smoking in smokers with 
schizophrenia.77 Other trials are underway to test the efficacy and acceptability of e-cigarettes 
for cessation in smokers with SMI.78,79(See Table 3) 
E-cigarettes are considerably less harmful than tobacco cigarettes and may be more 
acceptable than NRT for both smoking cessation and THR because of their sensory and 
behavioural similarities to cigarettes.80–82 Switching to snus is associated with substantial 
population health gains in Sweden.83 It has not been tested as a harm reduction option among 
smokers with SMI, but a clinical trial of snus among general population smokers did not find 
it better than high dose nicotine gum.84 Sales bans on these products in many developed 
countries such as Australia, New Zealand and the European Union (apart from Sweden) make 
it more difficult to conduct trials of THR.85 
There is a strong case for conducting pragmatic clinical trials of THR in smokers with serious 
mental illnesses. These should include trials of the use of e-cigarettes both for cessation from 
of all nicotine and as a long term alternative to smoking in those who are unable to stop using 
nicotine without relapsing to smoking. Conducting clinical trials among people with SMI can 
be challenging as their complex health and social needs can make recruitment, retention and 
monitoring more difficult than trials in general population samples.86 However, the extra 
investment and effort required to develop the evidence base for THR options for this 
population is warranted given the urgent need to reduce smoking among people with SMI. 
Conclusions  
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Smoking prevalence is very high among persons with SMI. The reasons are not wholly clear 
but the main contenders are self-medication, shared vulnerability due to environmental (e.g. 
social determinants of health) and/or genetic risk factors and a possible causal role for 
smoking. These are not necessarily mutually exclusive: smoking may have positive effects on 
some symptoms of SMI but at the cost of worsening other symptoms and increasing 
premature mortality and severe morbidity. 
Smokers with SMI appear to be as interested in quitting as smokers without these illnesses 
but find it difficult to quit and remain abstinent. Often, smokers with psychotic illnesses such 
as schizophrenia experience social isolation and stigma. This requires innovative approaches 
to improve their access to cessation methods that are effective in smokers in the general 
population.87  We need better evidence on whether these are as effective in persons with SMI. 
We also need more research on the effectiveness of delivering interventions via social media 
and smartphone apps and on long term relapse prevention in persons with SMI.88  
Questions have been raised about the ethics and effectiveness of smoking bans in mental 
health care facilities. These bans are often incompletely enforced because staff do not support 
them and are concerned about denying smokers who are treated involuntarily the “right to 
smoke”. The provision of NRT and other cessation aids during periods of hospitalisation 
should be an ethical minimum for the humane care of smokers with SMI. It should be 
accompanied by better efforts to encourage cessation after discharge. Comorbid alcohol and 
other substance abuse should not be considered a contraindication for smoking cessation in 
persons with SMI. 
A good case can be made for evaluating the role of e-cigarettes in smokers with SMI who try 
and fail to quit smoking. Thought may also be given to allowing their use in designated areas 
within hospitals that have banned cigarette smoking.  
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Search strategy and selection criteria 
 
Relevant literature was identified by searching prominent medical literature databases such 
as PubMed, Embase and CINAHL up to 7th  March 2016 using the search terms “severe 
mental illness”, “mental disorder”, “psychiatric”, “Schizophrenia”, “psychosis”, 
“depression” and  “bipolar disorder” alone and in combination with “smoking” , “tobacco”, 
“smoking cessation” , “quit smoking”, “harm reduction” , “tobacco harm reduction” , 
“smoking reduction” “electronic cigarette” , “e-cigarette”, “vaporiser”, “cannabis” , “snus”, 
“smoking ban” and “smoke free”. Papers were also identified from authors’ personal 
collections and from references cited in the included articles.  More emphasis was placed 
on recent publications. We generated the final reference list on the basis of the articles’ 
relevance to this paper. Preference was given to RCTs and Metanalysis of trials of cessation 
and harm reduction aids; and prospective observational studies and meta-analyses of these 
studies on associations between cigarette smoking and serious mental illnesses and impact 
of smoking bans in psychiatric hospitals. 
The site www.clinicaltrials.gov  was searched using the search terms: Smoking AND 
(“mental illness” OR schizophrenia OR depression OR bipolar). Only those trials which 
had their trial completion date listed as on or after January 2015 have been included in this 
list (Table 2). Trials with unknown status were excluded. 
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Table 1: Hypotheses for relationship between SMI and smoking  
Hypothesis Examples of Evidence for Hypothesis Examples of Evidence against Hypothesis 
Self-medication: 
People with SMI take 
up smoking to relieve 
their psychiatric 
symptoms 
Major Depression 
• Nicotine stimulates nicotinic acetylcholine receptors (nAChRs) 
in the brain which act on the acetylcholine, dopamine, 
norepinephrine, serotonin and opioids systems to enhance 
cognition and improve attention, memory, and mood.89 
• Monoamine oxidase inhibitors in cigarette smoke may have 
and antidepressant effect by inhibiting the breakdown of 
dopamine and serotonin.90 
• People with depression experience stronger withdrawal 
symptoms and negative affect on stopping smoking and 
smoking cessation can result in relapse to depression.7,91 
• Some antidepressants (bupropion and nortriptyline) are 
effective for smoking cessation.92,93 
 
Schizophrenia 
• Depressed mood is common in persons with schizophrenia; so 
any antidepressant effects of smoking are relevant to 
schizophrenia.94 
• Nicotine improves attention in people who experience deficits 
in filtering responses to sensory stimuli.90 Nicotine improves 
this deficit by activation of α 7 cholinoreceptors ,releasing 
Gamma-Aminobutyric acid (GABA)and decreasing 
glutamate.95 
• Nicotine may improve other sensory gating deficits such as 
prepulse inhibition (PPI) deficit and mismatch negativity 
(MMN) potentially improving startle responses and memory 
processing.95–97 
• Smoking relieves neuroleptic medication side effects such as 
Major Depression 
• Evidence demonstrates longer term 
improvement in depression and anxiety 
symptoms after smoking cessation.27 
• Most antidepressant drugs do not assist 
smoking cessation.33 
 
Schizophrenia 
• Smoking often starts before symptoms of 
schizophrenia appear.100 
• Nicotine does not have antipsychotic 
properties and treatment with antipsychotics 
does not aid in smoking cessation.101,102 
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parkinsonian symptoms and cognitive impairment.98,99  
 
Shared vulnerability: 
Smoking and severe 
mental illnesses coexist 
because of shared 
genetic/environmental 
risk factors and 
neurobiological 
aetiologies 
Major Depression 
• Twin studies suggest that the relationship between lifetime 
risks of smoking and major depression is solely due to shared 
genes that predispose to both conditions.18 
 
Schizophrenia 
• Genetic and environmentally based neuropathological 
abnormalities in the hippocampus and prefrontal cortex may 
increase vulnerability to the rewarding effects of addictive 
drugs and to experiencing psychotic symptoms.103 
• Genes such as CHRNA2, CHRNB2 ,CHRNA7 have been 
associated with regions that increase the risk of 
schizophrenia.104 
 
Bipolar disorder 
• Common genes (COMT, SLC6A3, and SLC6A4) and gene 
networks have been associated with both tobacco use disorder 
and bipolar disorder.105 
• Epidemiologic studies show that nicotine dependence and 
bipolar disorder predict each other’s development.106 
• Shared environmental factors such as alcohol and illicit drug 
use and childhood adversity predict the development of both 
smoking and bipolar disorder.107 
Major Depression 
• Family study of smoking and major 
depression did not find an increased risk of 
smoking among relatives of person with 
depression.108 
 
Schizophrenia 
• Genes strongly associated with an increased 
risk of developing schizophrenia are not 
associated with nicotine dependence or 
number of cigarettes per day.109 
 
 
 
 
 
 
 
 
 
 
 
 
 
Causal:  
Smoking causes SMI 
Major Depression 
• Epidemiological evidence indicates that cigarette smoking is 
associated with an increased risk of depression.110,111  
• A recent meta-analysis of 26 studies reported that smoking 
cessation is associated with reductions in depression and 
Major Depression 
• The likelihood of developing major 
depression in daily smokers is lower than in 
depressed individuals who start daily 
smoking (OR 1·9 vs OR 3·0). The 
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anxiety symptoms.27 
• Cigarette smoking may cause lower serotonin function in the 
hippocampus which may result in depression.112  
 
Schizophrenia 
• Nicotine increases dopamine release in the brain’s reward 
system.113 This is consistent with the hypothesis that psychotic 
symptoms are the result of increased levels of striatal 
dopamine.114 
• A meta-analysis of epidemiological studies shows that smoking 
often precedes the onset of psychotic symptoms, persons with 
psychotic symptoms are heaver smokers than those without, 
and these associations persist after controlling for potential 
confounders.115 
 
association may also be confounded by 
history of alcohol use.116  
• A Mendelian randomization metanalysis 
discounted a causal relationship as it did not 
find an association between a genetic 
marker for nicotine dependence (CHRNA5-
A3-B4 variant) and depression.117 
 
Schizophrenia 
• There are few prospective studies testing 
this hypothesis115 and stronger longitudinal 
evidence and  biological links are needed to 
establish a link between nicotine use and 
psychosis onset.118  The association between 
smoking and psychosis may be confounded 
by association between tobacco smoking 
and cannabis use.119 Cannabis use is 
associated with earlier onset of psychosis, 
has a dose response relationship with 
psychosis risk,118 and can produce psychotic 
symptoms in persons with and without 
psychoses.120 Only half of the prospective 
studies in the meta-analysis of tobacco use 
measured cannabis use.115 
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Table 2: Pros and cons of Smoking Bans 
Pros of smoking ban Cons  of smoking bans 
Protection of patients from smoking related harms Infringement of the “right to smoke” for involuntary patients 
and long term residents of psychiatric care facilities. 
Opportunity to quit smoking under the care of professionals and 
with access to smoking cessation therapies. 
Deterrent to seeking in-patient psychiatric treatment  
Protection of non-smokers from second-hand smoke Possibility of severe withdrawal symptoms mimicking 
exacerbation of mental illness 
Improvement in mental health on stopping smoking Some patients may leave the facility unaccompanied or 
discharge themselves early in order to smoke 
Possible reduction in doses of some anti-psychotic medications 
e.g. clozapine 
 
Prevention of relapse in patients and staff who have quit smoking  
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Table 3: Interventional trials for smoking cessation in people with severe mental illness. 
 
Title of the study Trial 
registry 
number 
Psychiatric 
condition 
Interventions Completion date Status 
Smoking Cessation for 
Depression and Anxiety 
Treatment 
NCT020
02858 
Depression and 
anxiety 
Nicotine Patch, Depression 
and Anxiety Smoking 
Cessation Treatment and 
Educational-Support 
Psychotherapy 
May 2016 Recruiting 
Decision Support for 
Smoking Cessation in 
Young Adults With Severe 
Mental Illness 
NCT017
79440 
Severe mental 
illness 
Varenicline and Placebo December 2015 Active, not recruiting 
Effects of Varenicline on 
Smoking Lapse in 
Smokers With and 
Without Schizophrenia 
NCT018
50953 
Schizophrenia Varenicline and Placebo May 2015 Completed 
Trial of Integrated 
Smoking Cessation, 
Exercise and Weight 
Management in Serious 
Mental Illness: TRIUMPH 
NCT024
24188 
Serious mental 
illness 
TRIIUMPH Intervention June 2019 Not yet recruiting 
Smoking Cessation for 
Depressed Smokers 
NCT004
94728 
Major 
Depression 
Smoking Cessation 
Treatment, Nicotine 
Replacement Therapy and 
Cognitive Behavioural 
Analysis System of 
Psychotherapy (CBASP) 
December 2016 Active, not recruiting 
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Effects of rTMS on 
Cigarette Smoking and 
Cognition in 
Schizophrenia 
NCT015
23730 
Schizophrenia Repetitive Transcranial 
Magnetic Stimulation 
(rTMS) and Sham Repetitive 
Transcranial Stimulation 
(rTMS) 
September 2015 completed 
Behavioural Activation 
and Varenicline for 
Smoking Cessation in 
Depressed Smokers 
NCT023
78714 
Depression Varenicline; behavioural 
activation for smoking 
cessation (BASC) and 
Standard treatment 
August 2020 Recruiting 
Novel Smoking Cessation 
Drug for Schizophrenia 
NCT022
30384 
Schizophrenia A novel drug and a placebo December 2016 Recruiting 
Study Evaluating The 
Safety And Efficacy Of 
Varenicline and Bupropion 
For Smoking Cessation In 
Subjects With And 
Without A History Of 
Psychiatric 
Disorders(EAGLES) 
NCT014
56936 
With and 
without 
psychiatric 
disorders 
Placebo, varenicline, 
bupropion hydrochloride and 
Nicotine Replacement 
Therapy Patch 
January 2015 
 
Completed 
Mobile Health Technology 
to Enhance Abstinence in 
Smokers With 
Schizophrenia 
NCT024
20015 
Schizophrenia Nicotine replacement 
therapy, Bupropion, 
cognitive-behavioural 
smoking cessation 
counselling, Mobile 
Contingency Management, 
Stay Quit Coach 
(smartphone application), 
SMS text messaging 
March 2018 Not yet recruiting 
Effects of Deep Breathing, 
Self-Help Book in 
NCT026
93561 
Anxiety and 
depression 
Deep Breathing Exercises 
and Self-Help Book 
August 2016 Recruiting 
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Cigarette Consumption, 
Anxiety, Depression and 
Motivation to Stop 
Smoking 
Smoking Cessation 
Following Psychiatric 
Hospitalization 
NCT022
04956 
Severe mental 
illness 
Extended Care and Brief 
Education 
June 2019 Not yet recruiting 
Electronic Cigarettes in 
Smokers With Mental 
Illness 
NCT022
12041 
Schizophrenia, 
Schizophrenifor
m Disorder, 
Bipolar 
Disorder 
Disposable electronic 
cigarette s 
June 2016 Not yet recruiting 
Telephone-based Smoking 
Cessation 
NCT025
00589 
Depression Behavioural mood 
management and Health 
education 
June 2019 Not yet recruiting 
Smoking Cessation And 
Reduction in Depression 
NCT021
24187 
Depression Ecig containing 24 mg 
nicotine, Ecig containing 
0mg nicotine and Nicotine 
free inhalator 
December 2017 Not yet recruiting 
Acute Effects of Exercise 
in Smokers With 
Schizophrenia 
NCT016
35075 
Schizophrenia Exercise and passive control January 2015 Completed 
Transcranial Direct 
Current Stimulation 
(tDCS) As A Treatment 
For Cigarette Craving and 
Cognitive Deficits in 
Schizophrenic 
NCT021
28919 
Schizophrenia Device: tDCS December 2017 Recruiting 
Randomized Controlled 
Trial (RCT) of a 
Motivational Decision 
NCT020
86162 
 
Schizophrenia Web-based motivational 
decision support system; and 
NCI (national cancer 
March 2017 Recruiting 
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Support System institute) Education 
Vigorous Exercise for 
Depressed Smokers 
NCT018
60924 
Depression Exercise and health 
education 
 
December 2015 Completed 
Exercise for Depressed 
Smokers 
NCT020
86149 
Depression Aerobic Exercise and Health 
Education 
September 2018 Recruiting 
Nicotine Receptor Density 
& Response to Nicotine 
Patch: Pt 2 Extended 
Treatment 
NCT026
76375 
Schizophrenia Standard therapy of Nicotine 
patch or bupropion and 
extended treatment with 
combination drugs with and 
without home visits and 
phone calls. 
February 2017 Active , not recruiting 
Effects of Varenicline on 
Plasticity in Schizophrenia 
NCT019
34023 
Schizophrenia Varenicline and Placebo 
 
August 2015 Completed 
Efficacy of N-Acetyl-
Cysteine in Bipolar 
Disorder and Tobacco Use 
Disorder 
NCT022
52341 
Bipolar disorder Dietary Supplement: N-
Acetyl-Cysteine 
September 2015 Enrolling by invitation 
Very Low Nicotine 
Cigarettes in Smokers 
With Schizophrenia 
NCT020
19459 
Schizophrenia Very low nicotine content 
cigarettes and standard 
nicotine content cigarettes 
August 2018 recruiting 
Contingency Management, 
Quitting Smoking, and 
ADHD 
NCT022
66784 
ADHD Contingency Management 
(CM); Transdermal nicotine 
skin patches (i.e. Habitrol) 
and Supportive Counselling 
October 2019 Recruiting 
Behavioural Activation for 
Smoking Cessation in 
Veterans With PTSD 
NCT019
47725 
PTSD Nicotine patch, Nicotine 
gum or nicotine lozenge, 
Standard Smoking Cessation 
September 2018 Recruiting 
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Therapy, Health and 
Smoking Education, 
Behavioral Activation 
Treatment 
CPT and Smoking 
Cessation 
NCT019
01848 
PTSD Cognitive Processing 
Therapy (CPT), Bupropion, 
nicotine replacement therapy 
(NRT), Integrated Care for 
Smoking Cessation (ICSC), 
smokefreeVET program 
April 2018 Recruiting 
Integrated PTSD and 
Smoking Treatment 
NCT019
88935 
PTSD Prolonged Exposure and 
Smoking Cessation 
counselling 
June 2018 Recruiting 
Behavioural Activation for 
Smoking Cessation in 
PTSD 
NCT019
95123 
PTSD Behavioural Activation 
Therapy, Health and 
Smoking Education and 
Standard Smoking Cessation 
Therapy 
December 2018 Recruiting 
Improving Functional 
Outcomes of Veterans 
With PTSD and Tobacco 
Dependence 
NCT025
76899 
PTSD Acceptance and 
Commitment Therapy for 
PTSD and Tobacco Use; and 
Freedom From Smoking 
program 
August 2017 Recruiting 
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Table 4: Pros and cons of using e-cigarettes for THR 
Pros of electronic cigarettes  Cons of electronic cigarettes 
A cleaner  source of nicotine than cigarettes when use for self-
medication 
Limited research on the harms or benefits of their long 
term use  
More economical than cigarettes in the long term Initially an electronic cigarettes kit costs more than a 
pack of cigarettes.  
Provides the socio-behavioural aspects of smoking on quitting. Some electronic cigarettes might be difficult to use by 
people with severe mental illness  
May result in smoking cessation/reduction because of diminished 
addiction potential of nicotine in the absence of any monoamine 
oxidase (MAO) inhibitors present in cigarette smoke. 
 
 
 
 
